

FIG. 1A




FIG. 1B

3/35




FIG. 1C

4/35




FIG. 1D




FIG. 1E

6/35




FIG. 2

7/35




FIG. 3

8/35




FIG. 4A




FIG. 4B



9/35




FIG. 4C




FIG. 4D

10/35




FIG. 4E

11/35




FIG. 5A




FIG. 5B

12/35




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 7A




FIG. 7B




FIG. 7C

16/35




FIG. 8A



17/35




FIG. 8B




FIG. 8C




FIG. 9A




FIG. 9B




FIG. 9C

22/35






FIG. 9D

23/35



**FIG. 10A**



**FIG. 10B**

24/35




FIG. 11A




FIG. 11B



25/35




FIG. 11C




FIG. 11D

26/35




FIG. 12A




FIG. 12B




FIG. 12C

27/35




FIG. 13A




FIG. 13B

28/35




FIG. 14A




FIG. 14B

29/35




FIG. 15A




FIG. 15B




FIG. 15C

30/35




FIG. 16




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 17D




FIG. 17E




FIG. 17F

32/35




FIG. 18




FIG. 19






FIG. 20A

34/35

| SAMPLE                      | AVG RLU/mg | STDEV    | FOLD CHANGE |
|-----------------------------|------------|----------|-------------|
| VEHICLE                     | 2.95E+03   | 9.01E+02 |             |
| AAV2 FLAG-LUCIFERASE        | 1.11E+05   | 3.77E+04 | 1.00        |
|                             |            |          |             |
| MG-132 - 20 $\mu$ M         | 1.43E+06   | 1.72E+06 | 12.90       |
|                             |            |          |             |
| DOXORUBICIN 6 $\mu$ g/ML    | 2.10E+07   | 4.57E+06 | 189.36      |
| DOXORUBICIN 3 $\mu$ g/ML    | 6.55E+06   | 1.15E+05 | 58.99       |
| DOXORUBICIN 0.6 $\mu$ g/ML  | 2.55E+05   | 1.30E+05 | 2.30        |
|                             |            |          |             |
| DAUNORUBICIN 6 $\mu$ g/ML   | 3.17E+08   | 1.41E+08 | 2855.65     |
| DAUNORUBICIN 3 $\mu$ g/ML   | 2.40E+07   | 2.72E+06 | 216.42      |
| DAUNORUBICIN 0.6 $\mu$ g/ML | 4.09E+05   | 6.41E+04 | 3.69        |
|                             |            |          |             |
| ELLENCE 6 $\mu$ g/ML        | 1.06E+08   | 4.85E+07 | 952.50      |
| ELLENCE 3 $\mu$ g/ML        | 1.33E+07   | 2.70E+06 | 120.13      |
| ELLENCE 0.6 $\mu$ g/ML      | 3.81E+05   | 1.78E+05 | 3.43        |
|                             |            |          |             |
| IDAMYCIN 6 $\mu$ g/ML       | 3.87E+04   | 2.00E+04 | 0.35        |
| IDAMYCIN 3 $\mu$ g/ML       | 5.99E+08   | 1.91E+08 | 5396.31     |
| IDAMYCIN 0.6 $\mu$ g/ML     | 5.30E+07   | 1.48E+07 | 477.76      |

FIG. 20B




FIG. 21